Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

CROC The natural K, Fe, and Cu isotopic response to Pt-based chemotherapeutic drug resistance in ovarian cancer

Coordinator
Universiteit Gent, Belgium
Runs
1 September 2024 to 31 August 2026
Status
Running
EU funding
€187k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101108731

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer is the second leading cause of death globally and in the EU, and was responsible for an estimated one in six deaths in 2018. Early diagnosis plays an important role in determining cancer treatment outcomes, but the diagnosis of ovarian cancer poses significant challenges; the routine screening of asymptomatic average-risk women is not recommended by any professional society. Chemotherapy using Pt-based compounds (e.g. carboplatin, cisplatin) is a standard treatment, but tumours that are initially responsive may develop chemoresistance, resulting in treatment failure.

The ability to predict patient response towards post-operative treatments would allow for ineffective treatments and harmful side effects to be avoided and alternative treatments to be commenced at earlier stages. Several mechanisms underlying tumour cell resistance have been identified so far, including the altered expression of ion channels (Na, Mg, K, and Ca) and Fe-, Cu-, and Zn-binding proteins, but these remain poorly understood and it is unclear whether they can be exploited as markers of resistance.

To that end, I will apply high-precision isotopic analysis by multicollector-inductively coupled plasma-mass spectrometry to Fe, K, and Cu to understand processes and determine whether changes in the natural abundances of these isotopes are associated with the development of resistance to Pt-based chemotherapeutic drugs in high-grade serous ovarian cancer (HGSOC), the deadliest gynaecological cancer, which accounts for ~70% of ovarian malignancies.

Deviations in natural isotopic abundances signal biochemical changes (affecting the extent of isotopic fractionation accompanying some biochemical processes) occurring as a result of a disease in a systematic and reliable way. Through ovarian cancer cell line, tumour spheroid, and HGSOC patient plasma experiments, I aim to develop a revolutionary, minimally-invasive prognostic marker of Pt-based chemotherapeutic drug resistance.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit GentGentBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI